Given the substantial evidence now suggesting that IKKα has an important role in a number of cancers [4] including inflammatory-driven solid tumour types such as prostate [31,32,33], colorectal [34,35], breast [23,36,37], and pancreatic [38,39,40], and in certain haematological tumours [4], there is a demand for selective IKKα inhibitors to dissect and validate its regulatory roles in tumour development and progression and establish its potential as a pharmacological target. Here, CHUK is linked to cancer.